| Abstrakt: |
The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin’s lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14+HLA-DRDIMcells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14+HLA-DRDIMratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14+HLA-DRDIM. With a median follow-up of 57.2 months (range: 2.1–84.6 months), patients with an A-NKC/A-CD14+HLA-DRDIMratio of ⩾0.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72–91%) vs 48% (95% CI, 34–62%), P<0.0002, respectively) and PFS (5-year PFS rates of 59% (95% CI, 47–71%) vs 32% (95% CI, 20–48%), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14+HLA-DRDIMratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95% CI, 0.32–0.96, P<0.03) and OS (HR=0.34, 95% CI, 0.16–0.68, P<0.002). The A-NKC/A-CD14+HLA-DRDIMratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT. |
Full text from SpringerLink